SEC Form 3 · accession 0001209191-15-026607

Arbutus Biopharma Corp · ABUS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Mar 4, 2015

Accepted (ET)

Mar 16, 2015 · 5:43 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001447028

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	holding	—	—		—	54,915	D
Common Stock^F2	holding	—	—		—	16,013,540	I	By Corporation

No Table II lines on this filing.

F1The reporting person held 54,530 shares of common stock of OnCore Biopharma, Inc. ("OnCore"). Pursuant to that certain Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among the issuer, TKM Acquisition Corporation and OnCore (the "Merger"), each issued and outstanding share of OnCore common stock was converted into 1.007062 common shares (rounded down) of the issuer. The closing of the Merger occurred on March 4, 2015.
F2These shares are owned by Roivant Sciences Ltd. ("Roivant"). Roivant held 15,901,246 shares of OnCore which converted into 16,013,540 shares of the issuer in the Merger at the same conversion rate as described in footnote (1) herein. The reporting person is one of three directors of Roivant and may be deemed to have the power to vote and dispose of the shares owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his pecuniary interest therein.

Exhibit List - Exhibit 24 - Power of Attorney